Research doesn't happen by accident. Clinical trials don't appear overnight. Every treatment we use at the bedside starts with years -- often decades -- of basic science, drug development, trial ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

The family of a young boy fighting cancer spoke with WMBF News on Sunday after finding out the seven-year-old is cancer-free.

Yale University held its 17th annual “Mandi Schwartz Marrow Donor Registration Drive” Tuesday, in an effort to save lives and honor a former hockey player who lost her battle with cancer. The ...

The researchers began by finding DNA aptamers that seek out markers found on the surface of acute myeloid leukemia stem cells ...

After his passing, the family started the Timothy O’Connell Foundation, raising more than a million dollars for research, ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

Ava Salonia, who played with the Oceanside Sailors, died at age 16 following a nearly 12-month battle with acute myeloid ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...